Patent application number | Description | Published |
20080228161 | Materials for Facilitating Administration of Dimethyl Sulfoxide (Dmso) and Related Compounds - The invention relates generally to materials for facilitating the administration of dimethyl sulfoxide (DMSO) and related compounds. In one embodiment, the invention comprises a kit comprising items used for the safe and effective administration of DMSO. In another embodiment, the invention relates to indicating containers for holding or delivering DMSO. | 09-18-2008 |
20080251081 | Systems for Removing Dimethyl Sulfoxide (Dmso) or Related Compounds or Odors Associated with Same - Preferred embodiments of the invention relate to systems for removing dimethyl sulfoxide (DMSO) or related compounds, or odors associated with same. The systems include adsorbents, odor adsorbing fabrics, masks, clean air members and clean air supply assemblies. | 10-16-2008 |
20110203583 | METHODS FOR FACILITATING USE OF DIMETHYL SULFOXIDE (DMSO) BY REMOVAL OF SAME, RELATED COMPOUNDS, OR ASSOCIATED ODORS - Several embodiments of the invention relate to methods for removing compositions comprising dimethyl sulfoxide (DMSO) or related compounds, or odors associated with same. In several embodiments, systems including activated carbon filters, adsorbents, odor adsorbing fabrics, masks, clean air members and clean air supply assemblies are provided in order to perform said methods. In some embodiments the systems and methods facilitating the treatment of traumatic brain injury, ischemic stroke, atherosclerosis, spinal cord trauma, and neurodegenerative illnesses with compositions comprising DMSO. | 08-25-2011 |
20110203584 | SYSTEMS FOR REMOVING DIMETHYL SULFOXIDE (DMSO) OR RELATED COMPOUNDS, OR ODORS ASSOCIATED WITH SAME - Preferred embodiments of the invention relate to systems for removing dimethyl sulfoxide (DMSO) or related compounds, or odors associated with same. The systems include adsorbents, odor adsorbing fabrics, masks, clean air members and clean air supply assemblies. | 08-25-2011 |
20110203585 | ACTIVATED CARBON SYSTEMS FOR FACILITATING USE OF DIMETHYL SULFOXIDE (DMSO) BY REMOVAL OF SAME, RELATED COMPOUNDS, OR ASSOCIATED ODORS - Several embodiments of the invention relate to systems and methods for removing compositions comprising dimethyl sulfoxide (DMSO) or related compounds, or odors associated with same. In several embodiments, the systems include activated carbon filters, adsorbents, odor adsorbing fabrics, masks, clean air members and clean air supply assemblies. Methods for reducing the concentration of a DMSO metabolite, or the odors associated with said DMSO metabolite are provided in some embodiments. In some embodiments the systems and methods facilitating the treatment of traumatic brain injury, ischemic stroke, atherosclerosis, spinal cord trauma, and neurodegenerative illnesses with compositions comprising DMSO. | 08-25-2011 |
20120207827 | DIMETHYL SULFOXIDE (DMSO) AND METHYLSULFONYLMETHANE (MSM) FORMULATIONS TO TREAT OSTEOARTHRITIS - Embodiments of the invention relate generally to the use of formulations comprising DMSO and MSM to treat arthritis (such as osteoarthritis), pain, inflammation, and/or degeneration. DMSO and MSM formulations are administered orally and/or topically in several embodiments and provide effective treatment of both chronic and acute symptoms of arthritis (e.g., osteoarthritis), pain, inflammation, and/or degeneration. Solid forms of DMSO are provided in several embodiments. | 08-16-2012 |
20130018059 | DIMETHYL SULFOXIDE (DMSO) FORMULATIONS FOR TREATING AUTISM - Embodiments of the invention relate generally to formulations comprising dimethyl sulfoxide (DMSO) to treat behavioral disorders, communication delays, and developmental delays. Several formulations disclosed herein are useful for treating broad autism phenotype disorders, including autism spectrum disorders (e.g., autism). | 01-17-2013 |
20130045941 | DIMETHYL SULFOXIDE (DMSO) OR DMSO AND METHYLSULFONYLMETHANE (MSM) FORMULATIONS TO TREAT INFECTIOUS DISEASES - Embodiments of the invention relate generally to formulations comprising dimethylsulfoxide (DMSO) alone or in combination with methylsulfonylmethane (MSM), and one or more therapeutic agents, and uses of such formulations to treat infectious diseases. In several embodiments, such formulations are effective in treating drug-resistant infectious diseases, for example, drug-resistant tuberculosis. | 02-21-2013 |
20140058337 | MATERIALS FOR FACILITATING ADMINISTRATION OF DIMETHYL SULFOXIDE (DMSO) AND RELATED COMPOUNDS - The invention relates generally to materials for facilitating the administration of dimethyl sulfoxide (DMSO) and related compounds. In one embodiment, the invention comprises a kit comprising items used for the safe and effective administration of DMSO. In another embodiment, the invention relates to indicating containers for holding or delivering DMSO. | 02-27-2014 |
20140116444 | DEVICES FOR REMOVAL OF DIMETHYL SULFOXIDE (DMSO) OR RELATED COMPOUNDS OR ASSOCIATED ODORS AND METHODS OF USING SAME - Several embodiments of the invention relate to devices for the removal of dimethyl sulfoxide (DMSO) or related compounds, or odors associated with DMSO or DMSO-related compounds. Several embodiments relate to methods of using the same. In several embodiments the devices include adsorbents, odor adsorbing fabrics, masks, clean air members and clean air supply assemblies. | 05-01-2014 |
20150290102 | TOPICAL SANITIZING FORMULATIONS AND USES THEREOF - Several embodiments disclosed herein relate to formulations having antimicrobial and/or sanitizing effects, and uses of the same. In particular, the formulations and methods of using same provide, in several embodiments, an immediate and a persistent antimicrobial effect against a broad spectrum of microorganisms. | 10-15-2015 |
Patent application number | Description | Published |
20110039929 | MICROBIOLOGICALLY SOUND AND STABLE SOLUTIONS OF GAMMA-HYDROXYBUTYRATE SALT FOR THE TREATMENT OF NARCOLEPSY - Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient. | 02-17-2011 |
20120020833 | MICROBIOLOGICALLY SOUND AND STABLE SOLUTIONS OF GAMMA-HYDROXYBUTYRATE SALT FOR THE TREATMENT OF NARCOLEPSY - Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient. | 01-26-2012 |
20120202879 | MICROBIOLOGICALLY SOUND AND STABLE SOLUTIONS OF GAMMA-HYDROXYBUTYRATE SALT FOR THE TREATMENT OF NARCOLEPSY - Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gammahydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient. | 08-09-2012 |
20120202880 | MICROBIOLOGICALLY SOUND AND STABLE SOLUTIONS OF GAMMA-HYDROXYBUTYRATE SALT FOR THE TREATMENT OF NARCOLEPSY - Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gammahydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient. | 08-09-2012 |
20130143965 | MICROBIOLOGICALLY SOUND AND STABLE SOLUTIONS OF GAMMA-HYDROXYBUTYRATE SALT FOR THE TREATMENT OF NARCOLEPSY - Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient. | 06-06-2013 |
20130267595 | MICROBIOLOGICALLY SOUND AND STABLE SOLUTIONS OF GAMMA-HYDROXYBUTYRATE SALT FOR THE TREATMENT OF NARCOLEPSY - Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient. | 10-10-2013 |
20150073052 | MICROBIOLOGICALLY SOUND AND STABLE SOLUTIONS OF GAMMA-HYDROXYBUTYRATE SALT FOR THE TREATMENT OF NARCOLEPSY - Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient. | 03-12-2015 |
20160058862 | MICROBIOLOGICALLY SOUND AND STABLE SOLUTIONS OF GAMMA-HYDROXYBUTYRATE SALT FOR THE TREATMENT OF NARCOLEPSY - Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gammahydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient. | 03-03-2016 |
Patent application number | Description | Published |
20090175920 | Biomaterial for osteosynthesis - The present invention relates to a biomaterial for the manufacture of osteosynthesis articles with dynamic mechanical properties analogous to calcified tissue, comprising a semi-aromatic polyamide matrix and at least one reinforcing means. | 07-09-2009 |
20110168957 | ELECTRICALLY CONDUCTIVE SOLID COMPOSITE MATERIAL, AND METHOD OF OBTAINING SUCH A MATERIAL - An electrically conductive solid composite material contains:
| 07-14-2011 |
20110300381 | Novel stable aqueous dispersions of high performance thermoplastic polymer nanoparticles and their uses as film generating agents - Novel aqueous dispersions of thermoplastic polymers suitable for generation of films, notably for the sizing of fibers for facilitating their handling and for making composite materials. | 12-08-2011 |
20120267563 | PIEZOELECTRIC AND/OR PYROELECTRIC COMPOSITE SOLID MATERIAL, METHOD FOR OBTAINING SAME AND USE OF SUCH A MATERIAL - A piezoelectric and/or pyroelectric composite solid hybrid material, includes: a solid dielectric matrix, a filler of at least one inorganic piezoelectric and/or pyroelectric material, wherein the filler includes filiform nanoparticles distributed throughout the volume of the solid dielectric matrix with an amount by volume of less than 50%, and in that the main directions of elongation of the filiform nanoparticles of the inorganic filler distributed in the dielectric matrix have a substantially isotropic distribution in the solid dielectric matrix. Also described is method for manufacturing and using such a hybrid material for producing structural parts and supported films deposited on the surface of such a substrate for: detecting mechanical stress by direct piezoelectric effect; detecting temperature variations by direct pyroelectric effect; creating a mechanical wave by reverse piezoelectric effect in a flexible audio device, in a de-icing device or in a mechanical anti-fouling device; and manufacturing a soundproof material. | 10-25-2012 |
20140256843 | BIOMATERIAL FOR OSTEOSYNTHESIS - A biomaterial for the manufacture of osteosynthesis articles is provided. The biomaterial contains a semi-aromatic polyamide matrix along with a reinforcing means selected to reinforce the matrix. The biomaterial has dynamic mechanical properties analogous to calcified tissue. | 09-11-2014 |
Patent application number | Description | Published |
20090163455 | AVERMECTIN/HYDROCORTISONE COMPOSITIONS FOR TREATING AFFLICTIONS OF THE SKIN, E.G., ROSACEA - Pharmaceutical/dermatological compositions containing at least one avermectin compound, e.g., ivermectin and hydrocortisone or salt, ester or derivative thereof, are useful for treating afflictions of the skin, especially rosacea. | 06-25-2009 |
20090163568 | AVERMECTIN/METRONIDAZOLE COMPOSITIONS FOR TREATING AFFLICTIONS OF THE SKIN, E.G., ROSACEA - Pharmaceutical/dermatological compositions containing at least one avermectin compound, e.g., ivermectin and metronidazole or salt, ester or derivative thereof, are useful for treating afflictions of the skin, especially rosacea. | 06-25-2009 |
20090233996 | AVERMECTIN/BENZOYL PEROXIDE COMPOSITIONS FOR TREATING AFFLICTIONS OF THE SKIN, E.G., ROSACEA - Pharmaceutical/dermatological compositions containing at least one avermectin compound, e.g., ivermectin and benzoyl peroxide, are useful for treating afflictions of the skin, especially rosacea. | 09-17-2009 |
20110003763 | AVERMECTIN/BENZOYL PEROXIDE COMPOSITIONS FOR TREATING AFFLICTIONS OF THE SKIN, E.G., ROSACEA - Pharmaceutical/dermatological compositions containing at least one avermectin compound, e.g., ivermectin and benzoyl peroxide, are useful for treating afflictions of the skin, especially rosacea. | 01-06-2011 |
20110033395 | AVERMECTIN/METRONIDAZOLE COMPOSITIONS FOR TREATING AFFLICTIONS OF THE SKIN, E.G., ROSACEA - Pharmaceutical/dermatological compositions containing at least one avermectin compound, e.g., ivermectin and metronidazole or salt, ester or derivative thereof, are useful for treating afflictions of the skin, especially rosacea. | 02-10-2011 |
20110052515 | AVERMECTIN/BENZOYL PEROXIDE COMPOSITIONS FOR TREATING AFFLICTION OF THE SKIN, E.G., ROSACEA - Pharmaceutical/dermatological compositions containing at least one avermectin compound, e.g., ivermectin and benzoyl peroxide, are useful for treating afflictions of the skin, especially rosacea. | 03-03-2011 |
20110165100 | COMPOSITIONS COMPRISING AVERMECTIN/AZELAIC ACID COMPOUNDS USEFUL FOR TREATING, E.G., ROSACEA - Pharmaceutical/dermatological compositions useful for the prevention/treatment of disorders of the skin, especially rosacea, contain thus effective amounts of at least one avermectin compound, e.g., ivermectin, and at least one azelaic acid compound or salt or derivative thereof, formulated into a physiologically acceptable medium therefor. | 07-07-2011 |
20110178049 | AVERMECTIN/HYDROCORTISONE COMPOSITIONS FOR TREATING AFFLICTIONS OF THE SKIN. E.G., ROSACEA - Pharmaceutical/dermatological compositions containing at least one avermectin compound, e.g., ivermectin and hydrocortisone or salt, ester or derivative thereof, are useful for treating afflictions of the skin, especially rosacea. | 07-21-2011 |
20110274631 | AVERMECTIN/METRONIDAZOLE COMPOSITIONS FOR TREATING AFFLICTIONS OF THE SKIN, E.G., ROSACEA - Pharmaceutical/dermatological compositions containing at least one avermectin compound, e.g., ivermectin and metronidazole or salt, ester or derivative thereof, are useful for treating afflictions of the skin, especially rosacea. | 11-10-2011 |
20120087876 | AVERMECTIN/METRONIDAZOLE COMPOSITIONS FOR TREATING AFFLICTIONS OF THE SKIN, E.G., ROSACEA - Pharmaceutical/dermatological compositions containing at least one avermectin compound, e.g., ivermectin and metronidazole or salt, ester or derivative thereof, are useful for treating afflictions of the skin, especially rosacea. | 04-12-2012 |
20130064780 | COMPOSITIONS COMPRISING AVERMECTIN/AZELAIC ACID COMPOUNDS USEFUL FOR TREATING E.G., ROSACEA - Pharmaceutical/dermatological compositions useful for the prevention/treatment of disorders of the skin, especially rosacea, contain thus effective amounts of at least one avermectin compound, e.g., ivermectin, and at least one azelaic acid compound or salt or derivative thereof, formulated into a physiologically acceptable medium therefor. | 03-14-2013 |
20130095051 | AVERMECTIN/METRONIDAZOLE COMPOSITIONS FOR TREATING AFFLICTIONS OF THE SKIN, E.G., ROSACEA - Pharmaceutical/dermatological compositions containing at least one avermectin compound, e.g., ivermectin and metronidazole or salt, ester or derivative thereof, are useful for treating afflictions of the skin, especially rosacea. | 04-18-2013 |
20140161747 | COMPOSITIONS COMPRISING AVERMECTIN/AZELAIC ACID COMPOUNDS USEFUL FOR TREATING, E.G., ROSACEA - Pharmaceutical/dermatological compositions useful for the prevention/treatment of disorders of the skin, especially rosacea, contain thus effective amounts of at least one avermectin compound, e.g., ivermectin, and at least one azelaic acid compound or salt or derivative thereof, formulated into a physiologically acceptable medium therefor. | 06-12-2014 |